An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy
Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
In light of recent evidence from the ATOMIC trial, balancing adjuvant and neoadjuvant immunotherapy approaches continues to challenge clinical decision-making.
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
Chrono-immunotherapy may influence treatment outcomes, especially during the early phase of treatment, but its overall clinical impact remains to be clearly defined
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
Dose optimisation of immune checkpoint inhibitors may help address current healthcare resource constraints and improve treatment access
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.